<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106973</url>
  </required_header>
  <id_info>
    <org_study_id>1432436</org_study_id>
    <nct_id>NCT04106973</nct_id>
  </id_info>
  <brief_title>Mesothelioma Early Detection by VOCs</brief_title>
  <acronym>MED-VOC</acronym>
  <official_title>Identification of Biomarkers for the Early Detection of Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension South East Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Association of Heat and Frost Insulators and Allied Workers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Owlstone Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujirebio Diagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascension South East Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two phase study, The first phase (phase 1) will identify potential biomarkers among&#xD;
      asbestos exposed individuals with pleural mesothelioma. The second phase (phase 2), is a&#xD;
      double blinded case-matched controlled study to determine the predictive capability,&#xD;
      sensitivity, and specificity of these biomarkers in detecting early stage pleural&#xD;
      mesothelioma. Biomarkers in the form of volatile organic compounds (VOC) in exhaled breath&#xD;
      samples from subjects with either pleural mesothelioma or pleural plaques, will be evaluated.&#xD;
      A biomarker present in serum will also be concurrently evaluated in the same cohort. The&#xD;
      soluble serum biomarker mesothelin related peptides (SMRP), which has been posited as a&#xD;
      biomarker for mesothelioma, will be analyzed for its relationship to the breath VOC profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mesothelioma is a rare, aggressive and treatment-resistant disease and, in the United States,&#xD;
      is caused almost exclusively by exposure to asbestos fibers. There is often a lengthy latency&#xD;
      period of 40-50 years between exposure and disease onset. The median age of diagnosis is 65&#xD;
      years while the median survival time after diagnosis of pleural mesothelioma without&#xD;
      treatment is 9 months. Symptoms, where present, may be non-specific, which further&#xD;
      contributes to delayed diagnosis.&#xD;
&#xD;
      In this study, the volatile organic compound (VOC) profile of exhaled breath from subjects&#xD;
      with histologically confirmed mesothelioma will be compared against case-matched control&#xD;
      subjects with bilateral pleural plaques or bilateral pleural thickening. Putative markers&#xD;
      will then be tested against a blinded cohort to test predictive value of the markers.&#xD;
&#xD;
      This study seeks to identify markers for mesothelioma using a non-invasive technique which&#xD;
      samples volatile organic compounds (VOC) in the breath of test subjects (Owlstone Medical&#xD;
      Ltd, Cambridge, England).&#xD;
&#xD;
      A comparison of the participant's VOC profile will be made with an FDA-approved, serum-based&#xD;
      assay (Lumipulse MesomarkÂ®, Fujirebio Diagnostics Inc., Malvern, PA) of the participant's&#xD;
      soluble mesothelin related peptides (SMRP) to discern parameters of efficacy..&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Recruitment suspended secondary to social distancing directive associated with Covid-19&#xD;
  </why_stopped>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VOC markers in breath samples. Predictive capability, sensitivity and specificity of biomarkers present in volatile organic compounds (VOC) for the early detection of pleural Mesothelioma in patients exposed to asbestos.</measure>
    <time_frame>At study completion, approximately 2 years</time_frame>
    <description>Predictive capability, sensitivity and specificity of biomarkers present in volatile organic compounds (VOC) for the early detection of pleural Mesothelioma in patients exposed to asbestos.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive capability, sensitivity and specificity of Soluble Mesothelin Related Peptides (SMRP) in serum when combined with VOC biomarkers for pleural mesothelioma.</measure>
    <time_frame>At study completion, approximately 2 years</time_frame>
    <description>Determine the additive predictive capability, sensitivity and specificity of SMRP serum biomarkers with VOC biomarkers for the early detection of pleural mesothelioma</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pleural Mesothelioma</condition>
  <condition>Asbestos Exposure</condition>
  <condition>Pleural Plaque</condition>
  <arm_group>
    <arm_group_label>Pleural mesothelioma</arm_group_label>
    <description>Participants with all types of histologically identified pleural mesothelioma prior to, subsequent to,or concurrent with treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asbestos exposed without pleural mesothelioma</arm_group_label>
    <description>Participants with asbestos exposure radiographically confirmed by the presence of bilateral pleural plaques or bilateral pleural thickening and without presence of pleural mesothelioma.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Exhaled breath collected in four stainless steel sorbent tubes and serum specimen and serum&#xD;
      specimen from each subject.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with histologically confirmed pleural mesothelioma, and individuals with an&#xD;
        asbestos exposure and radiological evidence of bilateral pleural plaques or pleural&#xD;
        thickening without evidence of mesothelioma. The majority of asbestos exposed participants&#xD;
        with bilateral pleural thickening or pleural plaques and no mesothelioma will be active or&#xD;
        retired members of the International Association of Heat and Frost Insulators and Allied&#xD;
        Workers Union.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or Female over 18 years of age&#xD;
&#xD;
          -  Clinical diagnosis of pleural mesothelioma or presence of pleural plaques on X-Ray&#xD;
&#xD;
          -  Documented exposure to asbestos&#xD;
&#xD;
          -  Must be able to provide breath sample&#xD;
&#xD;
          -  Must be able to provide relevant medical information&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Presence of malignancies other that mesothelioma within the past 6 months&#xD;
&#xD;
          -  Treatment for any malignancies other than mesothelioma within the past 6 months&#xD;
&#xD;
          -  Inability to provide past clinical information&#xD;
&#xD;
          -  Inability to perform breath collection procedure&#xD;
&#xD;
          -  Smoking or consuming alcohol within two hours of conducting breath collection&#xD;
             procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Harbut, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ascension Providence Hospital, Southfield</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Svinarich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ascension Providence South East Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consultants in Sleep and Pulmonary Medicine</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Oliver LC, Welch LS, Harbut MR. Comparison of B readers' interpretations of chest radiographs for asbestos related changes. Acad Radiol. 2004 Dec;11(12):1397-9; author reply 1402-4.</citation>
    <PMID>15596380</PMID>
  </reference>
  <results_reference>
    <citation>de Gennaro G, Dragonieri S, Longobardi F, Musti M, Stallone G, Trizio L, Tutino M. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure. Anal Bioanal Chem. 2010 Dec;398(7-8):3043-50. doi: 10.1007/s00216-010-4238-y. Epub 2010 Oct 6.</citation>
    <PMID>20924566</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ascension South East Michigan</investigator_affiliation>
    <investigator_full_name>David Svinarich, Ph.D.</investigator_full_name>
    <investigator_title>VP-Research</investigator_title>
  </responsible_party>
  <keyword>Pleural Mesothelioma</keyword>
  <keyword>Bilateral Pleural Plaques</keyword>
  <keyword>Asbestos Exposure</keyword>
  <keyword>Exhaled breath analysis</keyword>
  <keyword>VOCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

